Publications by authors named "A Paviglianiti"
Objective: This retrospective single center study aims to describe changes in the severity and organ-specific distribution of GvHD, by comparing the outcomes of 3 distinct GvHD prophylaxis approaches.
Methods: Between January 2012 and June 2022, 226 patients underwent allogeneic hematopoietic stem cell transplantation from HLA-matched or 1-allele mismatched related or unrelated donors. Fifty-eight (26%) received prophylaxis with calcineurin inhibitor in combination with mycophenolate mofetil or a short course of methotrexate (Cohort-1), 87 (38%) tacrolimus plus sirolimus (Cohort-2), and 81 (36%) post-transplant cyclophosphamide (PTCy) plus tacrolimus (Cohort-3).
Patients undergoing allogeneic stem cell transplant (HSCT) have a higher risk of developing malnutrition. The aetiology is multifactorial and complex: the conditioning regimen causes damages to the gastrointestinal tract that can contribute to trigger graft-versus-host disease and/or infectious complications that adversely affect food intake and the gut absorption of nutrients in transplant recipients. Consequently, patients might develop weight loss and muscle wasting.
View Article and Find Full Text PDFTelemedicine With Wearable Technologies in Patients Undergoing Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy (TEL-HEMATO Study): Prospective Noninterventional Single-Center Study.
JMIR Form Res
June 2024
Article Synopsis
- The TEL-HEMATO study focused on helping patients with blood cancers after they received special treatments called HCT and CAR T-cell therapy.
- They used wearable devices like smartwatches to track patients' health and how they're feeling in the first three months after they left the hospital.
- Results showed that most patients did well with tracking things like heart rate and steps, but not everyone remembered to check their temperature, and some had technology issues while using the system.
Article Synopsis
- * A low absolute lymphocyte count (ALC) on day +30 post-transplant was associated with a higher risk of reactivation (68%), while adding antithymocyte globulin (ATG) to GvHD prophylaxis did not significantly affect HHV6 reactivation rates.
- * Patients with HHV6 reactivation experienced delayed platelet recovery and an increased risk of acute GvHD, but their overall
Cell therapy, specifically the revolutionary chimeric antigen receptor (CAR) T-cell therapy, has transformed the landscape of oncology, making substantial strides in practical treatment approaches. Today, established guidelines for diseases such as lymphomas, myelomas, and leukemias actively advocate the utilization of these once-unconventional therapies. The practical impact of these therapies is underscored by their unparalleled efficacy, reshaping the way we approach and implement treatments in the realm of oncology.
View Article and Find Full Text PDF